ArticleScientific reports2025

PI3Kα-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells.

Benoît Thibault et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.